Back to results
US 2019/0292179 A1Published application
TGF Beta RECEPTOR ANTAGONISTS
AssigneeBristol-Myers Squibb Company
InventorsRobert M. Borzilleri, Peiyung Liu, Andrew J. Tebben, Upender Velaparthi, Hasibur Rahaman, Gopikishan Tonukunuru, Jayakumar Sankara Warrier
Life of this patent
Estimating the term…
Abstract
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Claims23
A compound having the structure of formula (Ia) or (Ib):
- or a pharmaceutically acceptable salt thereof,
- wherein
- A is phenyl substituted with 0-3 R4 groups or pyridyl substituted with 0-3 R4 groups;
- each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
- Z is a 10-12 membered heterobicyclic ring substituted with 0-2 RZ groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
- each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
- each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
- R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
- each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
- R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
- or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.
8 more elements
8-16. (canceled)
(canceled)
(canceled)
29-33. (canceled)
Dependencies are inferred from the claim text.